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The nature of the gain-of-function toxicity found in polyglutamine (polyQ) diseases has been the subject of
considerable debate. In this issue of Neuron, Duvick et al. and Nedelsky et al. show that, in two of these
diseases, pathology is mediated by normal protein activity.While many neurodegenerative diseases
have been linked to causative proteins,
controversy remains.Whendoes aprotein
contribute to disease through gain of
function (GOF), and when is it via loss of
function (LOF)? While the interpretation
(if not the molecular details) of patholog-
ical LOF is generally straightforward, the
etiology behind a GOF can be more
obscure. A GOF can be a novel property
that emerges in a disease-associated
protein, or it might result from an en-
hancement of one or more of the protein’s
normal functions to toxic levels.
Monogenic diseases offer tractable
models to examine the nature of a GOF.
Two papers in this issue of Neuron seek
to do just this by exploring in vivo models
of polyglutamine (polyQ) diseases. PolyQ
diseases include at least nine neurode-
generative diseases caused by a patho-
logical expansion of CAG repeats in the
coding regions of different genes (Orr
and Zoghbi, 2007). These diseases vary
remarkably in the susceptibility of specific
brain and spinal cord regions, and
together they represent the most com-
mon cause of inherited neurodegenera-
tive disease.
Direct toxicity of the polyQ stretch has
been hypothesized as a common mecha-
nism of polyglutamine diseases. In animal
models, a polyQ stretch is sufficient for
pathology and aggregation when inserted
into a larger protein (Ordway et al., 1997)
or as an independent peptide (Marsh
et al., 2000). In this model, the rest of the
protein influences only the details of the
death and dysfunction.
More recently, however, the protein
context has been shown to be critical,and in some cases polyQ expansion by it-
self is not sufficient for disease. For
instance, phosphorylation at serine 421
(Humbert et al., 2002) or serines 13 and
16 (Gu et al., 2009) of the protein that
causes Huntington’s disease (HD) abro-
gates its toxicity. The connection between
host protein context and toxicity suggests
that the normal function of the proteinmay
be linked to disease. Work by Nedelsky
et al. (2010) on spinal bulbar muscular
atrophy (SBMA) in this issue of Neuron
suggests just that.
SBMA is an X-linked neurodegenera-
tive disease characterized by late-onset
muscle weakness and wasting and
degeneration of motor neurons in the
brainstem and spinal cord (Orr and
Zoghbi, 2007). The polyQ expansion in
SBMA occurs in the androgen receptor
(AR), a classic nuclear hormone receptor.
This makes SBMA one of the few polyQ
diseases in which the function of the
host protein is well understood.
Nedelsky et al. (2010) combine existing
knowledge about the AR with the power
of fly genetics to home in on the source
of polyQ toxicity. The authors expressed
the human AR with wild-type (12Q) or
pathogenic (52Q) glutamine stretches in
the adult Drosophila eye or larval salivary
glands and motor neurons. In agreement
with previous findings, ligand binding
and nuclear translocation were necessary
to evoke the degenerative phenotype
(Katsuno et al., 2002; Takeyama et al.,
2002). Nuclear translocation alone was
insufficient; DNA binding was necessary
to cause degeneration. Thus, the first
steps of normal AR function are neces-
sary for toxicity.Neuron 67, SeAfter DNA binding, the AR normally
recruits transcriptional coregulators via
its AF-1 and AF-2 domains. Preventing
normal AF-2 interaction with coregulators
rescued the toxicity of mutant AR,
suggesting that normal AR-coregulator
interactions are necessary for disease.
Overexpression or knockdown of a
specific coregulator known to bind at the
AF-2 domain significantly affected the
degenerative phenotype. The authors
conclude that the polyQ expansion in the
AR mediates toxicity via normal AR inter-
actions. Which interactions are most
important for toxicity and their pathogenic
mechanism(s) remain unresolved.
How might normal interactions cause
toxicity? Two observations suggest that
toxicity is caused by enhanced AR
activity. First, high levels of expression of
wild-type AR showed a similar, yet more
minor, degenerative phenotype, implying
that high levels of normal AR activity,
even in the absence of the polyQ expan-
sion, are sufficient to cause degeneration.
Second, gene expression profiling
showed that expression of the wild-type
AR yielded changes similar to those
evoked by the mutant AR but to a lesser
degree. The similarity in gene expression
changes argues that the mild degenera-
tive phenotype seen in flies expressing
wild-type AR at high levels is not due to
a nonspecific toxicity of overexpression.
These data implicate polyQ-mediated
enhanced activity of wild-type function
as the source of toxicity in SBMA.
Independent work in this issue by
Duvick et al. (2010) on the polyQ disease
spinocerebellar ataxia type 1 (SCA1)
arrives at a similar conclusion. SCA1 isptember 23, 2010 ª2010 Elsevier Inc. 897
Figure 1. Conventional and Alternative Hypotheses on the Role of an Expanded PolyQ
Stretch
In the conventional view, a protein with a polyQ stretch (hatched region) has a specific normal function.
Expansion of the polyQ stretch causes disease due to an unrelated toxic gain of function (GOF) or
a loss of normal function (LOF). Alternatively, distinct protein conformations exist in equilibrium. The equi-
librium could be influenced in multiple ways, including chaperone binding (pink circle) and posttransla-
tional modifications, such as phosphorylation (yellow circle). PolyQ expansion disturbs the equilibrium,
leading to GOF associated with enhanced function of the stabilized conformer. There is also LOF due
to decreased function associated with the less preferred conformer. The polyQ expansion could affect
the equilibrium by stabilizing one of the conformers directly or by promoting an interaction with a confor-
mation-specific binding partner (not depicted), or indirectly by reducing chaperone availability through
stress on the proteostasis machinery.
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Previewscaused by a polyQ-expanded version of
the protein ataxin-1 and usually presents
in middle age as progressive ataxia,
tremor, and dysarthria. Pathology is char-
acterized by marked cerebellar atrophy
with Purkinje cell death (Orr and Zoghbi,
2007). Protein context is also important
in SCA1: phosphorylation at serine 776
of ataxin-1 is necessary for toxicity
(Emamian et al., 2003). Mutant ataxin-1
alters the balance of protein-protein inter-
actions between itself and two binding
partners, but abolishing phosphorylation
at S776 restores the wild-type equilibrium
(Lim et al., 2008). Intriguingly, mimicking
tonic phosphorylation by mutating serine
to aspartic acid (S776D) causes wild-
type ataxin-1 to interact with these
binding partners as if it were polyQ
expanded.
Duvick et al. (2010) follow up on this
finding to determine if wild-type ataxin-898 Neuron 67, September 23, 2010 ª2010 E1-S776D can evoke dysfunction and
pathology in vivo. They generated trans-
genic mice with Purkinje cell-specific
expression of the wild-type (30Q) or
mutant (82Q) ataxin-1 with the S776D
mutation. Mice expressing ataxin-1-82Q
demonstrated behavioral and histological
pathology (Orr and Zoghbi, 2007).
Furthermore, the ataxin-1-82Q-S776D
mice displayed similar pathology despite
significantly less transgene expression,
reflecting the enhanced toxicity of the
mimicked tonic phosphorylation. The
surprise camewith analysis of the respec-
tive wild-type ataxin-1-30Q mouse lines.
The ataxin-1-30Q-S776D cohort showed
atrophy of Pukinje cell dendritic branches
and a retraction of climbing fiber-Purkinje
cell synapses, similar to that seen in those
mice expressing mutant ataxin-1. The
rotarod confirmed a progressive func-
tional deficit. Hence, pathology causedlsevier Inc.by an expansion of a polyQ stretch was
evoked in mice by the same protein with
a nonmutant polyQ stretch if the phos-
phorylation site was mutated. It will be
interesting to see if polyQ expansion facil-
itates phosphorylation at S776 in vivo.
If polyQ expansion is not necessary for
ataxin-1 toxicity, then the wild-type func-
tions of ataxin-1 alone might be sufficient
for disease. Along these lines, mice
expressing ataxin-1-30Q with no alter-
ation at S776 showed evidence of
pathology. This line has the highest trans-
gene expression level, suggesting that
excessive levels of normal ataxin-1
activity represent the GOF caused by
polyQ expansion.
These two reports demonstrate that
normal function of the host protein is
crucial to pathogenesis in two distinct
polyQ diseases and implicate excessive
levels of normal function as the GOF that
causes toxicity. Are there any reasons to
worry that these model systems might
not fully reflect the mechanisms at play
in the human conditions? The AR has no
direct ortholog in flies, so its interactions
are occurring in a nonnative setting.
However, the AF-1 and AF-2 domains
are conserved in other native nuclear
hormone receptors in Drosophila, and
the majority of known human nuclear
hormone coregulators have orthologs in
the fly. Further, data from fly models of
SBMA have been broadly consistent
with those from mouse models (Katsuno
et al., 2002; Takeyama et al., 2002). It is
also worth considering the increasing
evidence of contributions to HD from cell
types other than neurons expressing the
polyQ expanded protein (Bradford et al.,
2009). If similar contributions are made
in other polyQ diseases, then they might
not be detected in the Drosophila eye or
in a mouse with restricted transgene
expression. Finally, any developmental
contribution to disease, as has been sug-
gested in the case of SCA1 (Orr and
Zoghbi, 2007), might be difficult to study.
Evidence for other causes of toxicity
in these diseases exists. In SBMA,
for example, patients can experience
gynecomastia and hypogonadism, signs
of mild androgen insensitivity. On the
other hand, frank feminization is not
observed, and loss of the AR does not
cause neurodegeneration (Orr and
Zoghbi, 2007), arguing against LOF as
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and LOF picture for SBMA may best
explain patient phenotypes, consistent
with in vitro data demonstating both up-
and downregulation of target genes by
mutant AR expression (Lieberman et al.,
2002).
The studies discussed here provide
clues as to how polyQ diseases could be
explained by a dominant GOF together
with a role for LOF (Figure 1). The host
proteinmight adopt one of several confor-
mations that depend on specific post-
translational modifications, e.g., phos-
phorylation, with different conformations
associated with particular functions. In
the disease setting, polyQ expansion
could stabilize certain conformations
of the host protein at the expense of
others, disrupting the equilibrium of pro-
tein conformations and enhancing the
functions associated with certain confor-
mations.
PolyQ expansions are also known to
place an extra burden on the protein
folding machinery (Powers et al., 2009).
Thus, disease might occur through dis-
rupted folding of other metastable
proteins, contributing to their LOF.
However, it is possible to imagine that
the burden on the chaperone system
could cause disease by enhancing
a normal function of the instigating polyQ
protein. A reduced availability of chaper-ones could shift the distribution of the
host protein’s conformers toward those
that do not require chaperones (Figure 1).
The increase in the function that corre-
sponds to that conformer would repre-
sent a GOF. Together, these changes
might bring about cell dysfunction and
eventual death.
These findings open the door to new
therapeutic opportunities. There are no
effective treatments for the polyQ
diseases, and the seemingly promising
approach of chemical castration for
SBMA failed a recent clinical trial (Katsuno
et al., 2010). These studies suggest that
targeting specific native protein functions
may be required for effective treatment.REFERENCES
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